George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024

1 year ago

George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at…

Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates

1 year ago

SHANGHAI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading…

Avricore Grants Options

1 year ago

VANCOUVER, British Columbia, Aug. 30, 2024 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) today announces…

Vision Sensing Acquisition Corp. Announces Intention to Extend the Period to Consummate Its Initial Business Combination to October 3, 2024

1 year ago

NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special…

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

1 year ago

Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML…

Jushi Holdings Inc. Announces Filing of Canadian Preliminary Base Shelf Prospectus

1 year ago

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES BOCA RATON, Fla., Aug. 30,…

Receipt of Nasdaq Delisting Determination – Plans to Appeal

1 year ago

August 30, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”)Receipt of Nasdaq Delisting Determination Plans to Appeal Biodexa Pharmaceuticals PLC (Nasdaq:…

Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update

1 year ago

All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Rakovina…

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

1 year ago

DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee…

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

1 year ago

- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that…